Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07209410 · ClinicalTrials.gov registry record · Phase 4
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
A Phase 4 study of Glaucoma, sponsored by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07209410: Recruiting Phase 4 study of Glaucoma, sponsored by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,.
NCT07209410 is a Phase 4 study of Glaucoma that is actively recruiting participants, run by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,. The registered enrollment target is 35 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07209410, a Phase 4 study of Glaucoma, is actively recruiting participants, sponsored by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.
Primary Outcome
Measuring Ocular Hyperemia and injection. This is measured on Scale 0-4 0- Normal 1. Trace 2. Mild 3. Moderate 4. Severe
Conditions Studied
Interventions
- DRUG Brimonidine Tartrate Ophthalmic 0.025%
Study Locations (1)
Missouri
- Vision Source - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 4 |
What NCT07209410 shows while recruiting
NCT07209410 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Brimonidine Tartrate Ophthalmic 0.025% is the first listed.
NCT07209410 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT07209410 about?
NCT07209410 is a clinical study titled "Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma". To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.
What is the current status of trial NCT07209410?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2025-11-01. Estimated completion is 2027-06-01.
What conditions does trial NCT07209410 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT07209410?
The interventions under investigation include: Brimonidine Tartrate Ophthalmic 0.025% (DRUG).
Who is sponsoring clinical trial NCT07209410?
This trial is sponsored by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07209410 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07209410's enrollment target sits among peer trials
35 77th of 92 higher than 15 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI